Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$17.24 USD
+0.56 (3.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $18.00 +0.76 (4.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TVTX 17.24 +0.56(3.36%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TVTX
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insight
Q2 2025 Travere Therapeutics Inc Earnings Call Transcript
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Travere Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation